Neurochemical and structural correlates of executive dysfunction in schizophrenia

Schizophrenia Research

Volumn 99, Issue 1-3, 2008, Pages 155-163

  Rüsch, Nicolas ^a,b   Tebartz van Elst, Ludger ^a,b   Valerius, Gabi ^a,b   Büchert, Martin ^a,b   Thiel, Thorsten ^a,b   Ebert, Dieter ^a,b   Hennig, Jürgen ^a,b   Olbrich, Hans Martin ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b South German Brain Imaging Center   (Germany)

Author keywords

Amygdala; Executive dysfunction; Glutamate; Schizophrenia; Spectroscopy; Volumetry

Indexed keywords

AMISULPRIDE; CLOZAPINE; FLUPHENAZINE; GLUTAMIC ACID; GLUTAMINE; HALOPERIDOL; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT; HIPPOCAMPUS; HUMAN; MALE; MONOTHERAPY; NEUROCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARANOID SCHIZOPHRENIA; PATIENT ASSESSMENT; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SPECTROSCOPY; VOLUMETRY;

ADULT; AMYGDALA; ASPARTIC ACID; ATROPHY; BRAIN; COGNITION DISORDERS; DOMINANCE, CEREBRAL; FEMALE; GLUTAMIC ACID; GLUTAMINE; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROPSYCHOLOGICAL TESTS; PREFRONTAL CORTEX; PROBLEM SOLVING; SCHIZOPHRENIA, PARANOID;

EID: 39049122010     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.05.024     Document Type: Article

References (49)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) (1994), American Psychiatric Association, Washington DC
2. Antonova E., Sharma T., Morris R., and Kumari V. The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophrenia Research 70 (2004) 117-145
3. Barch D.M. What can research on schizophrenia tell us about the cognitive neuroscience of working memory?. Neuroscience 139 (2006) 73-84
4. Bartha R., Williamson P.C., Drost D.J., Malla A., Carr T.J., Cortese L., Canaran G., Rylett R.J., and Neufeld R.W. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Archives of General Psychiatry 54 (1997) 959-965
5. Benes F.M., and Berretta S. Amygdalo-entorhinal inputs to the hippocampal formation in relation to schizophrenia. Annals of the New York Academy of Sciences 911 (2000) 293-304
6. Bertolino A., Esposito G., Callicott J.H., Mattay V.S., Van Horn J.D., Frank J.A., Berman K.F., and Weinberger D.R. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. American Journal of Psychiatry 157 (2000) 26-33
7. Bertolino A., Sciota D., Brudaglio F., Altamura M., Blasi G., Bellomo A., Antonucci N., Callicott J.H., Goldberg T.E., Scarabino T., Weinberger D.R., and Nardini M. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. American Journal of Psychiatry 160 (2003) 483-489
8. Bilder R.M., Bogerts B., Ashtari M., Wu H., Alvir J.M., Jody D., Reiter G., Bell L., and Lieberman J.A. Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophrenia Research 17 (1995) 47-58
9. Braus D.F., Ende G., Weber-Fahr W., Demirakca T., Tost H., and Henn F.A. Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. European Neuropsychopharmacology 12 (2002) 145-152
10. Corrigan P.W., and Penn D.L. Social Cognition and Schizophrenia (2001), American Psychological Association, Washington DC
11. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., and Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences 98 (2001) 6917-6922
12. Everett J., Lavoie K., Gagnon J.-F., and Gosselin N. Performance of patients with schizophrenia on the Wisconsin Card Sorting Test. Journal of Psychiatry & Neuroscience 26 (2001) 123-130
13. Farber N.B. The NMDA receptor hypofunction model of psychosis. Annals of the New York Academy of Sciences 1003 (2003) 119-130
14. Goldberg T.E., and Gold J.M. Neurocognitive deficits in schizophrenia. In: Hirsch CNCO S.R., and Weinberger D.R. (Eds). Schizophrenia (1995), Blackwell Science, Oxford 146-162
15. Green M.F., and Nuechterlein K.H. Should schizophrenia be treated as a neurocognitive disorder?. Schizophrenia Bulletin 25 (1999) 309-319
16. Gur R.E., Cowell P.E., Latshaw A., Turetsky B.I., Grossman R.I., Arnold S.E., Bilker W.B., and Gur R.C. Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Archives of General Psychiatry 57 (2000) 761-768
17. Gur R.E., Turetsky B.I., Cowell P.E., Finkelman C., Maany V., Grossman R.I., Arnold S.E., Bilker W.B., and Gur R.C. Temporolimbic volume reductions in schizophrenia. Archives of General Psychiatry 57 (2000) 769-775
18. Heaton R.K., Chelune G.J., Talley J.L., Kay G.G., and Curtiss G. Wisconsin Card Sorting Test Manual, Revised and Expanded. 2nd edn. (1993), Psychological Assessment Resources, Odessa, Florida
19. Honea R., Crow T.J., Passingham D., and Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. American Journal of Psychiatry 162 (2005) 2233-2245
20. Imre G., Fokkema D.S., Den Boer J.A., and Ter Horst G.J. Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Research Bulletin 69 (2006) 338-345
21. Konradi C., and Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacology and Therapeutics 97 (2003) 153-179
22. Kubicki M., McCarley R., Westin C.F., Park H.J., Maier S., Kikinis R., Jolesz F.A., and Shenton M.E. A review of diffusion tensor imaging studies in schizophrenia. Journal of Psychiatric Research 41 (2007) 15-30
23. Levin E.D., McClernon F.J., and Rezvani A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 184 (2006) 523-539
24. Lewis D.A., and Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Archives of Neurology 63 (2006) 1372-1376
25. Lipska B.K., and Weinberger D.R. A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus. Neurotoxicity Research 4 (2002) 469-475
26. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40 (2003) 881-884
27. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Melson A.K., Hershey T., Craft S., and Olney J.W. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20 (1999) 106-118
28. Ohnishi T., Hashimoto R., Mori T., Nemoto K., Moriguchi Y., Iida H., Noguchi H., Nakabayashi T., Hori H., Ohmori M., Tsukue R., Anami K., Hirabayashi N., Harada S., Arima K., Saitoh O., and Kunugi H. The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. Brain 129 (2006) 399-410
29. Ohno M., Yamamoto T., and Watanabe S. Amygdaloid NMDA and muscarinic receptors involved in working memory performance of rats. Physiology and Behavior 54 (1993) 993-997
30. Ohrmann P., Siegmund A., Suslow T., Pedersen A., Spitzberg K., Kersting A., Rothermundt M., Arolt V., Heindel W., and Pfleiderer B. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. Journal of Psychiatric Research 41 (2007) 625-634
31. Olbrich, H.M., Valerius, G., Rüsch, N., Büchert, M., Thiel, T., Hennig, J., Ebert, D., Tebartz van Elst, L., in press. Frontolimbic glutamate alterations in first episode schizophrenia: Evidence from a magnetic resonance spectroscopy study. World Journal of Biological Psychiatry.
32. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance Medicine 30 (1993) 672-679
33. Reich D.L., and Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Canadian Journal of Anaesthesia 36 (1989) 186-197
34. Ross A.J., and Sachdev P.S. Magnetic resonance spectroscopy in cognitive research. Brain Research Reviews 44 (2004) 83-102
35. Rowland L.M., Bustillo J.R., Mullins P.G., Jung R.E., Lenroot R., Landgraf E., Barrow R., Yeo R., Lauriello J., and Brooks W.M. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. American Journal of Psychiatry 162 (2005) 394-396
36. Rüsch N., Spoletini I., Wilke M., Bria P., Dia Paola M., Di Iulio F., Martinotti G., Caltagirone C., and Spalletta G. Prefrontal-thalamic-cerebellar gray matter networks and executive functioning in schizophrenia. Schizophrenia Research 93 1-3 (2007) 79-89 (Jul)
37. Seidman L.J., Yurgelun-Todd D., Kremen W.S., Woods B.T., Goldstein J.M., Faraone S.V., and Tsuang M.T. Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia. Biological Psychiatry 35 (1994) 235-246
38. Shenton M.E., Dickey C.C., Frumin M., and McCarley R.W. A review of MRI findings in schizophrenia. Schizophrenia Research 49 (2001) 1-52
39. Smith R.C., Singh A., Infante M., Khandat A., and Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27 (2002) 479-497
40. Steen R.G., Hamer R.M., and Lieberman J.A. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 30 (2005) 1949-1962
41. Szeszko P.R., Strous R.D., Goldman R.S., Ashtari M., Knuth K.H., Lieberman J.A., and Bilder R.M. Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia. American Journal of Psychiatry 159 (2002) 217-226
42. Tebartz van Elst L., Valerius G., Büchert M., Thiel T., Rüsch N., Bubl E., Hennig J., Ebert D., and Olbrich H.M. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biological Psychiatry 58 (2005) 724-730
43. Tebartz van Elst L., Valerius G., Büchert M., Thiel T., Rüsch N., Bubl E., Hennig J., Ebert D., and Olbrich H.M. Lack of empirical reference data for in vivo magnetic resonance spectroscopic glutamate measurements in humans. Biological Psychiatry 61 10 (2007) 1219-1226
44. Theberge J., Bartha R., Drost D.J., Menon R.S., Malla A., Takhar J., Neufeld R.W., Rogers J., Pavlosky W., Schaefer B., Densmore M., Al Semaan Y., and Williamson P.C. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. American Journal of Psychiatry 159 (2002) 1944-1946
45. Theberge J., Al Semaan Y., Williamson P.C., Menon R.S., Neufeld R.W., Rajakumar N., Schaefer B., Densmore M., and Drost D.J. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. American Journal of Psychiatry 160 (2003) 2231-2233
46. Tsai G., Yang P., Chung L.C., Lange N., and Coyle J.T. d-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 44 (1998) 1081-1089
47. Weinberger D.R., Berman K.F., Suddath R., and Torrey E.F. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. American Journal of Psychiatry 149 (1992) 890-897
48. Yeo R.A., Hodde-Vargas J., Hendren R.L., Vargas L.A., Brooks W.M., Ford C.C., Gangestad S.W., and Hart B.L. Brain abnormalities in schizophrenia-spectrum children: implications for a neurodevelopmental perspective. Psychiatry Research 76 (1997) 1-13
49. Yeo R.A., Hill D., Campbell R., Vigil J., and Brooks W.M. Developmental instability and working memory ability in children: a magnetic resonance spectroscopy investigation. Developmental Neuropsychology 17 (2000) 143-159